Module contents

Module home

Module introduction

Module information

Related articles: Advances in Psychiatric Treatment

About the authors

Pre-module test

 

Section 1: Introduction and epidemiology

(1.1) Section 1: Introduction and epidemiology

(1.2) Introduction and epidemiology

(1.3) Introduction and epidemiology

(1.4) Epidemiology of stimulant misuse

(1.5) Interactive exercise: epidemiology of stimulant misuse

(1.6) Section 1: Recap

(1.7) Section 1: Summary

 

Section 2: Cocaine and crack cocaine

(2.1) Section 2: Cocaine and crack cocaine

(2.2) Difference between cocaine and crack cocaine

(2.3) Cocaine: misuse among the general population

(2.4) Reflection

(2.5) Reflection: answer

(2.6) Crack cocaine: misuse among the general population

(2.7) Cocaine: misuse among young adults

(2.8) Patterns of use and socio-demographics

(2.9) Profiles of cocaine users

(2.10) Treatment demand indicator

(2.11) Reflection

(2.12) Reflection: answer

(2.13) Cocaine-related deaths

(2.14) Section 2: Recap

(2.15) Section 2: Summary

 

Section 3: Amphetamine, methamphetamine and ecstasy

(3.1) Section 3: Amphetamine, methamphetamine and ecstasy

(3.2) Interactive exercise: definitions

(3.3) Amphetamine, methamphetamine and ecstasy: misuse among the general population

(3.4) Amphetamine and methamphetamine: misuse among young adults

(3.5) Amphetamine and methamphetamine: treatment demand indicator

(3.6) Amphetamine- and methamphetamine-related deaths

(3.7) Ecstasy: misuse among the general population

(3.8) Reflection

(3.9) Reflection: answer

(3.10) Ecstasy: misuse among young adults

(3.11) Ecstasy: patterns of use

(3.12) Ecstasy: treatment demand indicator

(3.13) Ecstasy-related deaths

(3.14) Section 3: Recap

(3.15) Section 3: Summary

 

Section 4: Novel psychoactive substances

(4.1) Section 4: Novel psychoactive substances

(4.2) Novel psychoactive substances

(4.3) BZP and piperazine derivatives

(4.4) Mephedrone and cathinone derivatives

(4.5) Mephedrone and cathinone derivatives

(4.6) Mephedrone-related deaths

(4.7) Naphyrone

(4.8) 4,4-DMAR

(4.9) Methylphenidate-like NPS

(4.10) Synthetic cocaine analogs

(4.11) Section 4: Recap

(4.12) Section 4: Summary

 

Section 5: Stimulant misuse: impact on mental health

(5.1) Section 5: Stimulant misuse: impact on mental health

(5.2) Introduction

(5.3) Dual diagnosis

(5.4) Substance-induced psychiatric disorders

(5.5) Interactive exercise: cocaine: impact on mental health

(5.6) Cocaine: impact on mental health

(5.7) Clinical vignette: cocaine

(5.8) Amphetamines: impact on mental health

(5.9) Psychopathological consequences

(5.10) Interactive exercise: clinical signs of amphetamine intoxication

(5.11) Amphetamine-induced psychosis

(5.12) Amphetamine withdrawal symptoms

(5.13) Amphetamine neurotoxicity

(5.14) Amphetamine: clinical vignette

(5.15) Ecstasy: impact on mental health

(5.16) Psychoactive effects

(5.17) Neurocognitive problems

(5.18) Impact on serotonin levels

(5.19) Acute and long-term consequences

(5.20) Clinical vignette: ecstasy

(5.21) Mephedrone: impact on mental health

(5.22) Clinical vignette: mephedrone

(5.23) Section 5: Recap

(5.24) Section 5: Summary

 

Module summary

Module test

Acknowledgements

Send feedback

 

Useful resources

Take-home notes

References

Further reading

© 2019 Royal College of Psychiatrists